ELAVL2 is an RNA-binding protein that regulates gene expression primarily through 3' untranslated region (3'UTR) binding, recognizing GAAA motifs and stabilizing target mRNAs including FOS and ID transcripts 1. In neurons, ELAVL2 plays a critical role in RNA homeostasis by modulating 3'UTR length and regulating dsRNA formation, which impacts innate immune signaling; ELAVL2 depletion shortens 3'UTRs, reduces immunostimulatory dsRNA levels, and increases viral susceptibility 2. ELAVL2 also regulates neurodevelopmental gene networks linked to autism spectrum disorder through post-transcriptional mechanisms affecting both transcript expression and alternative splicing 1. Beyond the nervous system, ELAVL2 functions in testicular spermatogonial stem cells where it promotes proliferation and inhibits apoptosis via ERK/AKT pathway activation 3, and is reduced in patients with non-obstructive azoospermia. ELAVL2 has emerging clinical relevance in primary ovarian insufficiency where pathogenic variants were identified in a large genetic study 4. Additionally, ELAVL2 cooperates with long non-coding RNA SNHG3 to stabilize SNAI2 in trabecular meshwork cells under oxidative stress, relevant to glaucoma pathogenesis 5, and regulates glycolytic enzyme expression affecting chemotherapy resistance in ovarian cancer 6. ELAVL2 participates in neural tube development through the Zic3-ApoM-Elavl2-Nnt axis controlling mitophagy and apoptosis balance 7.